Peptides That Bind to Amino-Terminal Truncated Amyloid-Beta-Peptide and Use of Said Peptides

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention covers specific synthetic peptides that selectively bind to N-terminally truncated (pyroglutamate-modified) forms of amyloid-beta peptide, which are prevalent in Alzheimer's disease pathology. These peptides are based on D-amino acids, which makes them highly resistant to enzymatic breakdown in the body. The peptides can help both in the early diagnosis and the potential treatment of Alzheimer's by either detecting disease-related amyloid-beta species via imaging techniques or by interfering with their aggregation and toxicity.

Use CasesContent extracted from patent full text and abstract with AI.

• Diagnostic imaging agents (e.g., PET, SPECT, MRI) for early detection of Alzheimer's disease by labeling amyloid plaques in the brain.
• Therapeutic agents for the treatment or prevention of Alzheimer's by binding toxic amyloid-beta species and neutralizing or reducing their aggregation and neurotoxicity.
• Research tools to study the presence and distribution of specific amyloid-beta species in neurodegenerative diseases.
• Development of diagnostic kits for Alzheimer's screening using patient samples (e.g., cerebrospinal fluid, blood).

BenefitsContent extracted from patent full text and abstract with AI.

• Highly specific binding to the toxic, truncated forms of amyloid-beta linked to Alzheimer's, enhancing diagnostic accuracy and therapeutic effect.
• Peptides composed of D-amino acids are resistant to degradation by natural enzymes, resulting in longer in vivo stability and reduced side effects.
• Potential to diagnose Alzheimer’s disease at a much earlier stage, before symptoms arise, by targeting pathological markers directly.
• May allow for more effective and targeted intervention in Alzheimer’s disease progression compared to current approaches that do not focus on these truncated species.
• Possibility of differentiating Alzheimer's from other neurodegenerative diseases by targeting unique amyloid-beta isoforms.
• Reduced immunogenicity compared to natural peptides, minimizing adverse immune responses.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to peptides which bind to amino-terminal truncated pEAβ3-42, the free glutamic acid group of which lies in position 3 or 11 in the form of cyclized pyroglutamate. Four oligopeptides were identified using mirror image phage display technology.